Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Children's Health System, Dallas, Texas, USA.
Transfusion. 2024 Oct;64(10):1860-1869. doi: 10.1111/trf.17997. Epub 2024 Sep 8.
Trauma remains the leading cause of pediatric mortality in the United States. Although use of massive transfusion protocols (MTPs) in this population is widespread, optimal pediatric resuscitation is not well established. We sought to assess contemporary pediatric MTP practice in the United States.
A web-based survey was designed by the Association for the Advancement of Blood & Biotherapies (AABB) Pediatric Transfusion Medicine Subsection and distributed to select American College of Surgeons (ACS) Level I Verified pediatric trauma centers. The survey assessed current MTP policy, implementation, and recent changes in practice.
Response rate was 55% (22/40). Almost half of the respondents were from the South. The median RBC:plasma ratio was 1 (interquartile range 1-1.5). Protocolized fibrinogen supplementation was common while integration of antifibrinolytic therapy into MTPs was infrequent. Viscoelastic testing (VET) was available at most sites, 71% (15/21, one site did not respond), and was generally utilized on an ad-hoc basis. Roughly, a third of sites had changed their MTP in the past 3 years due to blood supply issues, and about a third reported having group O Whole Blood on-site.
MTP practice is similar throughout the United States. Though fibrinogen supplementation is common-other emerging interventions such as antifibrinolytic therapy or utilization of routine viscoelastic testing-are not widespread. Pediatric transfusion medicine experts must continue to follow practice change, as contemporary large trials begin to characterize new supportive modalities to optimize resuscitation in pediatric trauma patients.
在美国,创伤仍然是导致儿科死亡的主要原因。尽管在该人群中广泛使用大量输血方案(MTP),但并未很好地确立最佳儿科复苏方法。我们旨在评估美国当代儿科 MTP 实践。
由血液和生物疗法协会(AABB)儿科输血医学分部设计的基于网络的调查,并分发给选定的美国外科医师学会(ACS)一级验证儿科创伤中心。该调查评估了当前的 MTP 政策、实施情况以及近期实践中的变化。
应答率为 55%(22/40)。近一半的受访者来自美国南部。红细胞:血浆比中位数为 1(四分位距 1-1.5)。普遍实施了方案化纤维蛋白原补充,但将抗纤维蛋白溶解疗法纳入 MTP 的情况并不常见。大多数中心都可进行粘弹性测试(VET),71%(21/15,一个中心未回复),并且通常是临时使用。大约三分之一的中心在过去 3 年内因血液供应问题改变了 MTP,约三分之一的中心报告称现场有 O 型全血。
美国各地的 MTP 实践相似。尽管纤维蛋白原补充较为常见,但其他新兴干预措施(如抗纤维蛋白溶解疗法或常规粘弹性测试的使用)并不广泛。儿科输血医学专家必须继续关注实践变化,因为当代大型试验开始描述新的支持性治疗方法,以优化儿科创伤患者的复苏。